Share Prices & Company Research


12 April 2018

Redmayne Bentley’s Top Trades

Index: FTSE 250
Sector: Pharmaceuticals & Biotechnology
Market Capitalisation: £2,464.82m
Shares in global healthcare company BTG fell sharply following a preclose trading update last week, falling to an annual low of 592.5p. The group said that revenue for the year to the end of March was in line with expectations, with “very good growth in Interventional Medicine product sales”. However, investors were disappointed by lower sales of the PneumRx Coils, which are not expected to pick up for a couple of years. Final results are due to be published on 15th May.
Index: FTSE 100
Sector: Automobiles & Parts
Market Capitalisation: £7,461.76m
Earlier this year, engineering firm GKN rejected an unsolicited bid of 405p per share from manufacturing turnaround company Melrose Industries. That offer valued GKN at £7bn, which it considered to “fundamentally undervalue” the group. However, late last month, Melrose received the
backing of 52% of GKN shareholders to acquire the 259 year-old engineering group for £8bn in a mixture of cash and shares. Melrose said its strategy is “to improve all of the businesses in GKN, only realising their value once they have reached full potential.”
Index: FTSE 100
Sector: Pharmaceuticals & Biotechnology
Market Capitalisation: £32,561.1m
Irish-based drugs maker Shire Pharmaceuticals recently saw its shares drift to their lowest level since 2014 and warned in its final results, published in February, that profits in 2018 would be hit by competition from new generic drugs. However, shares spiked higher last month following news that Japan’s Takeda Pharmaceutical was “considering making an approach” for the group. Takeda has been very active in making acquisitions, having recently bought US oncology group Ariad Pharmaceuticals for US$5.2bn and Swiss drugs company Nycomed for US$13.7bn.
Top Trades is published every fortnight in Equity Insight, a newsletter written by our stockbrokers and investment managers. It provides market commentary, a focus on individual sectors, technical analysis, potential trading opportunities and share reviews.
Please note that investments and income arising from them can fall as well as rise in value and you may lose some or all of the amount you have invested. Past performance and forecasts are not a reliable indicator of future results or performance. Please note that this communication is for information only and does not constitute a recommendation to buy or sell the shares of the companies mentioned.
Redmayne Bentley’s Top Trades
Newsletter sign up
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.